Windtree Therapeutics, a biotech firm that had recently implemented a BNB treasury strategy, saw its stock plummet 77% following notice of its delisting from the Nasdaq for noncompliance with minimum bid price requirements. The Nasdaq informed Windtree that it failed to meet the criteria outlined in Listing Rule 5550(a)(2), which mandates that a stock must maintain a minimum bid price of $1.00 per share. As a result, Windtree's shares dropped to $0.11, continuing to decline in after-hours trading. The company had previously announced a $60 million purchase agreement related to its BNB treasury strategy, but this optimistic outlook quickly turned sour. Despite the delisting, CEO Jed Latkin stated that Windtree would continue to meet its financial reporting obligations. Other firms adopting similar BNB strategies have seen varied outcomes in the market, underscoring the risks associated with such shifts in investment strategy. As the broader crypto market shows signs of a rebound, BNB itself recorded gains, reaching a new all-time high.

Source đź”—